Comparative Pharmacology
Head-to-head clinical analysis: LIQUID E Z PAQUE versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUID E Z PAQUE versus MD 76R.
LIQUID E-Z-PAQUE vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Terminal half-life 1-2 hours; prolonged in renal impairment.
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent